logo

Clinical Trial Calendar

Share
Company Name Alnylam Pharmaceuticals Inc.
Event Name Top Line Data from ENDEAVOUR Phase 3 Study with Revusiran
Indication Treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM) (familial amyloidotic cardiomyopathy)
Outcome Date 10/05/2016
Outcome DMC, on Oct.5, 2016, asked Company to discontinue study; Stock down over 41%
Result Date Early 2018
News
https://finance.yahoo.com/news/alnylam-pharmaceuticals-discontinues-revusiran-development-203000616.html
Return to Clinical Trial Calendar